The use of recombinant human granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation.
To examine the effects of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients undergoing autologous bone marrow transplantation (ABMT), a series of phase I, II, and III trials was done. rhGM-CSF was given to patients undergoing ABMT for lymphoid neoplasia beginning 2 h after marrow infusion. The results indicate that rhGM-CSF is well tolerated and stimulates early neutrophil and platelet recovery. rhGM-CSF did not affect relapse or survival. Patients who received rhGM-CSF had fewer infections, less marrow transplant-related toxicity, and shorter hospital stays than control patients.
Nemunaitis
J
J
Department of Veterans Affairs Medical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Singer
J W
JW
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D007958:Leukocyte Count; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D009504:Neutrophils; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor